Advancing Major Depressive Disorder Treatment: Exxua™ (gepirone extended release) Approval and Potential Impact

Major Depressive Disorder (MDD) is a significant health concern impacting millions of American adults each year, with over 8% affected annually. Diagnosis involves identifying specific symptoms, including persistent low mood, anhedonia, guilt, lack of energy, concentration problems, appetite and sleep changes, and thoughts of self-harm. According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), diagnosing MDD requires at least five of these symptoms, with depressed mood or anhedonia causing social or occupational impairment being one of the symptoms. The disorder’s etiology is complex, involving biological, genetic, environmental, and psychosocial factors. Understanding the multifaceted nature of MDD is essential in addressing its prevalence and varied presentations. <a href="https://inpharmd.medium.com/advancing-major-depressive-disorder-treatment-exxua-gepirone-extended-release-approval-and-f1de26e19c4f">Read More</a>